“…The long-term outcome and revision rates after THA in patients with previous pediatric hip disease have been studied (Thillemann et al 2008, Traina et al 2011), but 90-day mortality and overall mortality after THA in these patients have not yet been investigated. Comorbidities, such as attention deficit hyperactivity disorder (ADHD), depression, cardiovascular disease, hypothyroidism, obesity, and coagulation abnormalities are more common in patients with LCPD and SCFE (Hailer and Nilsson 2014, Perry et al 2017, Hailer and Hailer 2018, Hailer 2020). In addition, patients with LCPD and SCFE have a higher overall mortality than the general population (Hailer andNilsson 2014, Hailer 2020).…”